Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 223

The DOI matches its Crossref record.

Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients

Su, Tung‐Hung, Hu, Tsung‐Hui, Chen, Chi‐Yi, Huang, Yi‐Hsiang, Chuang, Wan‐Long, Lin, Chun‐Che, Wang, Chia‐Chi, Su, Wei‐Wen, Chen, Ming‐Yao, Peng, Cheng‐Yuan, Chien, Rong‐Nan, Huang, Yi‐Wen, Wang, Horng‐Yuan, Lin, Chih‐Lin, Yang, Sheng‐Shun, Chen, Tsung‐Ming, Mo, Lein‐Ray, Hsu, Shih‐Jer, Tseng, Kuo‐Chih, Hsieh, Tsai‐Yuan, Suk, Fat‐Moon, Hu, Chi‐Tan, Bair, Ming‐Jong, Liang, Cheng‐Chao, Lei, Yung‐Chao, Tseng, Tai‐Chung, Chen, Chi‐Ling, Kao, Jia‐Horng, the C‐TEAM study group and the Taiwan Liver Diseases Consortium · 2016 · Liver International

Abstract

Background & Aims: Oral antiviral therapy may reduce the disease progression of chronic hepatitis B (CHB) patients. We aimed to further investigate the efficacy of long‐term entecavir therapy in reduction of the risk of hepatocellular carcinoma (HCC), cirrhotic events and mortality in a large group of CHB‐related cirrhosis patients. Methods: The C‐TEAM (Cirrhosis‐Taiwanese EntecAvir Multicenter) study was a nationwide, multicenter, retrospective–prospective cohort study in Taiwan. We enrolled treatment‐naïve patients with CHB‐related cirrhosis and baseline HBV‐DNA≥2000 IU/mL receiving long‐term entecavir therapy and compared the development of HCC, cirrhotic events and mortality with that of a historical untreated cohort. Results: In total, 1315 entecavir‐treated and 503 untreated patients with cirrhosis were enrolled, with median treatment and follow‐up durations of 4 and 6 years respectively. Compared with the untreated cohort, entecavir therapy was associated with a 60% HCC risk reduction [hazard ratio (HR): 0.40, 95% confidence interval (CI): 0.28‐0.57]. Additionally, an older age, the male gender, HBeA g positivity, alpha‐fetoprotein (AFP)≥7 ng/mL before therapy were independent predictors of HCC development. Further analysis showed that entecavir therapy significantly reduced risks of variceal bleeding, spontaneous bacterial peritonitis, and liver‐related and all‐cause mortality. These findings were confirmed by propensity score‐matched cohorts in sensitivity analysis. In patients under entecavir therapy, an older age, the male gender, HBeA g positivity, AFP level ≥7 ng/mL before therapy, and 1‐year virological response were predictive of HCC development. Conclusions: Four‐year entecavir therapy significantly reduces the risk of HCC, cirrhotic events and mortality in patients with CHB‐related cirrhosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/liv.13253

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 223

Metadata

Authors
Su, T., Hu, T., Chen, C., Huang, Y., Chuang, W., Lin, C., Wang, C., Su, W., Chen, M., Peng, C., Chien, R., Huang, Y., Wang, H., Lin, C., Yang, S., Chen, T., Mo, L., Hsu, S., Tseng, K., Hsieh, T., Suk, F., Hu, C., Bair, M., Liang, C., Lei, Y., Tseng, T., Chen, C., Kao, J., & the C‐TEAM study group and the Taiwan Liver Diseases Consortium
Venue
Liver International
Publisher
Wiley
Published
2016-10-04
Volume
36
Issue
12
Pages
1755-1764
ISSN
  • 0106-9543 (ISSN-L)
  • 1478-3223
  • 1478-3231
OpenAlex
W2519375936
Cited by
223
References
0
FWCI
19.08
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. https://app.cochat.ai/papers/10.1111/liv.13253
The paper
Su, T., Hu, T., Chen, C., Huang, Y., Chuang, W., Lin, C., Wang, C., Su, W., Chen, M., Peng, C., Chien, R., Huang, Y., Wang, H., Lin, C., Yang, S., Chen, T., Mo, L., Hsu, S., Tseng, K., . . . the C‐TEAM study group and the Taiwan Liver Diseases Consortium. (2016). Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver International. https://doi.org/10.1111/liv.13253

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.